| Autor: |
Quián YP; From the *Direction for Clinical Research, Isotope Center, Havana, Cuba; and †Center of Molecular Immunology, Havana, Cuba., Crombet T, Batista JF, Prats A, Perera A |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical nuclear medicine [Clin Nucl Med] 2016 Mar; Vol. 41 (3), pp. 244-6. |
| DOI: |
10.1097/RLU.0000000000001011 |
| Abstrakt: |
Detection of bone metastases indicates poor prognosis for patients with prostate cancer. The immunotherapy with monoclonal antibody has been an important advance in the treatment of the cancer in the last years. Nimotuzumab is a humanized IgG1 monoclonal antibody directed against epidermal growth factor receptor that has been evaluated in solid tumors. The authors show images of 2 patients with bone metastases secondary to prostate cancer, "pre-cold therapy" with nimotuzumab. Immunoscintigraphic images were acquired 4 and 24 hours after the intravenous administration of 1110 MBq (30 mCi) of Tc-labeled nimotuzumab. Bone metastases expressing the receptor are visualized. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
